Gabriel N. Hortobagyi

The University of Texas MD Anderson Cancer Center
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (21)

PURPOSE Clinicopathological factors and the 21-gene Oncotype DX Breast Recurrence Score (RS) test both influence prognosis. Our goal was to develop a new tool, RSClinN+, to individualize recurrence risk and chemotherapy benefit predictions by menopausal status for patients with HR+/human epidermal growth factor receptor 2–negative, lymph node–positive breast cancer by integrating the RS result with clinicopathological factors (grade, tumor size, age). METHODS We used patient-level data from 5,283 patients treated with chemoendocrine therapy (CET) versus endocrine therapy alone (ET) in the S1007 (N = 4,916) and S8814 (N = 367) trials to develop the tool. Cox proportional hazards regression models stratified by trial were used to estimate 5-year invasive disease-free survival for pre- and postmenopausal woman, respectively. The integrated RSClinN+ model was compared with RS alone and clinicopathological models using likelihood ratio tests. Absolute CET benefit was estimated as the difference between ET and CET risk estimates. Validation of RSClinN+ was performed in 592 patients with node-positive disease in the Clalit Health Services registry. RESULTS RSClinN+ provides better prognostic information than RS model alone (premenopausal P = .034; postmenopausal P < .001) or clinicopathological model alone (premenopausal P = .002; postmenopausal, P < .001). In postmenopausal women, RS showed interaction with CET benefit ( P = .016), with RSClinN+ absolute CET benefit ranging from <0.1% to 21.5% over RS ranges 0-50. In premenopausal patients with RS ≤25, there was no significant interaction between RS and CET benefit. In external validation, RSClinN+ risk estimates were prognostic (hazard ratio, 1.75 [95% CI, 1.38 to 2.20]) and concordant with observed risk (Lin's concordance, 0.92). CONCLUSION RSClinN+ provides improved estimates of prognosis and absolute CET benefit for individual patients compared with RS or with clinical data alone and could be used in patient counseling.

Year:

2025

Purpose: The phase III NATALEE trial reported a statistically significant invasive disease-free survival benefit with ribociclib plus nonsteroidal aromatase inhibitor (NSAI) versus an NSAI alone in stage II/III hormone receptor–positive, HER2-negative (HR+/HER2−) early breast cancer. In this study, we report health-related quality of life (HRQOL) data from NATALEE. Patients and Methods: Patients were randomized to receive ribociclib plus NSAI or NSAI alone. Patient-reported outcome scores [European Organisation for Research and Treatment of Cancer core quality of life questionnaire global health status and physical, social, and emotional functioning domains; the supplementary European Organisation for Research and Treatment of Cancer breast cancer–specific QOL questionnaire breast symptoms scale; health on a visual analog scale of the generic EuroQOL 5-level instrument; and the Hospital Anxiety and Depression Scale] were assessed. The prespecified primary HRQOL endpoint was physical functioning. Mean scores and time-categorical and prespecified linear-time repeated-measure models were used to evaluate HRQOL changes during treatment. Results: HRQOL was evaluated in all patients in the ribociclib plus NSAI ( n = 2,549) and NSAI alone ( n = 2,552) arms. Compliance was high in both arms (≈93%–97%). Mean scores did not differ meaningfully from baseline for any analyzed domain. Likewise, neither a meaningful change from baseline (in either treatment arm) nor a difference between arms was observed during treatment in the time-categorical, model-adjusted mean scores for any HRQOL domains—using published thresholds for interpreting longitudinal and between-group differences, with all values being within 0.5 SD of their baseline values. Linear-time regression analysis confirmed these findings. Conclusions: These analyses of NATALEE show that adding adjuvant ribociclib to an NSAI does not negatively affect HRQOL in patients with HR+/HER2− early breast cancer.

Year:

2025

Somatic mutations identified by whole exome sequencing. Oncoplot representing the most common somatic mutations assessed by whole exome sequencing (WES) in tumors obtained from patients (n = 23) at the time of diagnosis. Genes with mutations occurring in five or more patients are shown.

Year:

2025

Purpose: Epidermal growth factor receptor (EGFR) pathway activation causes chemotherapy resistance, and inhibition of the EGFR pathway sensitizes triple-negative breast cancer (TNBC) cells to chemotherapy in preclinical models. Given the high prevalence of EGFR overexpression in TNBC, we conducted a single-arm phase II study of panitumumab (anti-EGFR monoclonal antibody), carboplatin, and paclitaxel as the second phase of neoadjuvant therapy (NAT) in patients with doxorubicin and cyclophosphamide (AC)–resistant TNBC (NCT02593175). Patients and Methods: Patients with early-stage, AC-resistant TNBC, defined as disease progression or ≤80% reduction in tumor volume after four cycles of AC, were eligible for this study and received panitumumab (2.5 mg/kg i.v., every week × 13), paclitaxel (80 mg/m 2 i.v. every week × 12), and carboplatin (AUC = 4 i.v., every 3 weeks × 4) as the second phase of NAT. A two-stage Gehan-type design was used to detect an improvement in the pathological complete response (pCR)/residual cancer burden class I (RCB-I) rate from 5% to 20%. Whole-exome sequencing was performed on diagnostic tumor biospecimens, where available. Results: From November 3, 2016, through August 23, 2021, 43 patients with AC-resistant TNBC were enrolled. The combined pCR/RCB-I rate was 30.2%. The most common treatment-related adverse events were neutropenia (72%) and anemia (61%), with 7 (16%), 16 (37%), and 8 (19%) patients experiencing grade 4 neutropenia, grade 3 neutropenia, and grade 3 anemia, respectively. No new safety signals were observed. Conclusions: This study met its primary endpoint (pCR/RCB-I = 30.2% vs. 5% in historical controls), suggesting that panitumumab should be evaluated as a component of NAT in patients with chemotherapy-resistant TNBC in a larger, randomized clinical trial. Significance: The epidermal growth factor receptor (EGFR) pathway has been implicated as a driver of chemotherapy resistance in triple-negative breast cancer (TNBC). Here, we evaluate the combination of panitumumab, carboplatin, and paclitaxel as the second phase of neoadjuvant therapy (NAT) in patients with AC-resistant TNBC. This study met its primary efficacy endpoint, and molecular alterations in EGFR pathway genes did not seem to influence response to the study regimen.

Year:

2025

Response to AC. Waterfall plot showing percent sonographic volumetric change to initial AC chemotherapy received prior to enrollment in study. One of the 43 patients enrolled in this study is not represented on this plot as an ultrasound was not done at the end of AC. Colors represent the total number of cycles of AC received prior to enrollment in study (red = 1; gray = 2; blue = 4). Horizontal dashed line indicates an 80% decrease in calculated tumor volume when compared with baseline measurements.

Year:

2024

Genomic alterations and pathological response to therapy. Oncoplot showing somatic mutations in the EGFR pathway assessed by WES for each patient sample obtained at the time of diagnosis ( n = 23). TMB was defined as the number of somatic mutations per megabase (Mb) of the sequenced genome.

Year:

2024

Somatic mutations identified by whole exome sequencing. Oncoplot representing the most common somatic mutations assessed by whole exome sequencing (WES) in tumors obtained from patients (n = 23) at the time of diagnosis. Genes with mutations occurring in five or more patients are shown.

Year:

2024

Survival outcomes. A, Kaplan–Meier plot of EFS for all patients. B, Kaplan–Meier plot of EFS separated by pathological response. C, Kaplan–Meier plot of MFS for all patients. D, Kaplan–Meier plot of MFS separated by pathological response. E, Kaplan–Meier plot of OS for all patients. F, Kaplan–Meier plot of OS separated by pathological response.

Year:

2024

Triple-negative breast cancer (TNBC) has high relapse and metastasis rates and a high proportion of cancer stem-like cells (CSC), which possess self-renewal and tumor initiation capacity. MELK (maternal embryonic leucine zipper kinase), a protein kinase of the Snf1/AMPK kinase family, is known to promote CSC maintenance and malignant transformation. However, the role of MELK in TNBC metastasis is unknown; we sought to address this in the current study. We found that MELK mRNA levels were higher in TNBC tumors [8.11 (3.79–10.95)] than in HR + HER2 − tumors [6.54 (2.90–9.26)]; P 0.001]. In univariate analysis, patients with breast cancer with high- MELK –expressing tumors had worse overall survival ( P 0.001) and distant metastasis-free survival ( P 0.01) than patients with low- MELK –expressing tumors. In a multicovariate Cox regression model, high MELK expression was associated with shorter overall survival after adjusting for other baseline risk factors. MELK knockdown using siRNA or MELK inhibition using the MELK inhibitor MELK-In-17 significantly reduced invasiveness, reversed epithelial-to-mesenchymal transition, and reduced CSC self-renewal and maintenance in TNBC cells. Nude mice injected with CRISPR MELK-knockout MDA-MB-231 cells exhibited suppression of lung metastasis and improved overall survival compared with mice injected with control cells ( P P Significance: These findings indicate that MELK is a driver of aggressiveness and metastasis in TNBC.

Year:

2024

Effect of inhibition of MELK signaling on tumor growth and lung metastasis in TNBC xenograft mouse models. A, MELK expression in Cas9-p15 (P15) and MELK KO MDA-MB-231 (C3 and C28) cells. α-Tubulin was used as a loading control. B–F, MELK KO significantly suppressed lung metastases in an MDA-MB-231 xenograft mouse model. Female athymic nude mice were injected intravenously with luciferase-transfected Cas9-p15 or MELK KO MDA-MB-231-Luc-GFP stable cells. Metastatic tumors were measured weekly for 7 weeks by whole-body luciferase imaging using an IVIS 100 Imaging System. Shown are mouse whole-body luciferase images ( B ), photon counts per area ( C ), lung weight per mouse measured at week 7 following cell inoculation ( D ), mouse OS over a period of 80 days following cell inoculation ( E ), and IHC staining for hematoxylin and eosin (H&E), MELK, proliferation (Ki67), and mesenchymal markers (vimentin and fibronectin; F ) in mice inoculated with Cas9-p15 or MELK KO MDA-MB-231 cells. Images were taken under 200 × magnification. G, MELK-In-17 significantly suppressed tumor growth in a 4T1 xenograft mouse model ( P 3 , grouped mice were treated with vehicle or MELK-In-17 at 5 or 10 mg/kg via intraperitoneal injections daily for 25 days. In C–G, data are presented as mean ± SD. *, P P

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Collaborators (27)

Naoto Ueno

Professor of Medicine

University of Hawai'i Cancer Center

UNITED STATES
View details

Lajos Pusztai

Yale University

UNITED STATES
View details

Xiaoping Wang

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Yu Shen

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Sherene Loi

University of Melbourne

AUSTRALIA
View details

Jennifer K. Litton

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Steven Van Laere

Full Professor

University of Antwerp

BELGIUM
View details

Zbigniew Nowecki

Head od Department

Maria Sklodowska-Curie National Research Institute of Oncology

POLAND
View details

Anil Korkut

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Jeffrey Chang

The University of Texas Health Science Center at Houston

UNITED STATES
View details

Hope Rugo

Director, Women’s Cancer Program Division; Professor, Department of Medical Oncology & Therapeutics Research; Chief, Breast Medical Oncology

City Of Hope National Medical Center

UNITED STATES
View details

Bora Lim

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Dennis J. Slamon

University of California, Los Angeles

UNITED STATES
View details

James Rae

University of Michigan

UNITED STATES
View details

Kevin N. Dalby

Professor

University of Texas at Austin

UNITED STATES
View details

Geoffrey Bartholomeusz

Associate Professor, Director Target Identification and Validation Program

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Peter Fasching

-

GERMANY
View details

Ryan Sun

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Elizabeth Mittendorf

Harvard University

UNITED STATES
View details

Banu K. Arun

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Sara Hurvitz

Professor, Division Head

Washington University School of Medicine

UNITED STATES
View details

Alastair M Thompson

Professor of Surgery

Baylor College of Medicine

UNITED STATES
View details

Lei Huo

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Senthil Damodaran

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Miguel Martin

Universidad Complutense de Madrid

SPAIN
View details

Ken Chen

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Miral M Patel

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details